CureVac banks $213M IPO to push COVID-19 vaccine, boost manufacturing

Franz-Werner Haas, interim CEO of CureVac
CureVac CEO Franz-Werner Haas (CureVac)

On the heels of a $640 million private round, Germany’s CureVac has netted $213 million in its Nasdaq debut. The bulk of the proceeds will bankroll its mRNA vaccine for COVID-19, with the rest going to manufacturing, platform development and other programs.

The company also picked up another $118 million through a private placement to longtime investor, Dietmar Hopp, according to Renaissance Capital. All of this cash comes in even before CureVac’s COVID-19 candidate has put up any human data.

Like its peers, Moderna and tandem BioNTech/Pfizer, CureVac is developing an mRNA vaccine against SARS-CoV-2, the virus that causes COVID-19. But it is trailing its peers, whose candidates are already in late-stage trials. CureVac secured approvals from Belgian and German authorities in June to conduct a phase 1 trial. That’s not to say CureVac should be counted out—in pandemic that will likely need as many vaccines as possible, it will still have a potentially big role in the R&D effort.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

RELATED: CureVac closes $640M investment amid COVID-19 vaccine race

The company will spend about $150 million of its IPO proceeds push its COVID-19 vaccine program through a phase 3 study and about $50 million to expand its short-term manufacturing capabilities, it said in a securities filing.

It earmarked another $25 million for its lead cancer program, CV8102, which is in phase 1 for various cancers, including melanoma and head and neck cancers, and about $10 million for its rabies vaccine, CV7202, also in phase 1. The capital should push them both through phase 2 studies, according to the filing. Finally, about $65 million will go toward developing its mRNA technology platform and advancing its other preclinical and clinical programs.

The IPO comes a week after CureVac signed a new chief scientific officer, Novartis alum Igor Splawski, Ph.D., and settled on a full-time CEO after months of executive musical chairs. Daniel Menichella, the company’s CEO since 2018, mysteriously exited in March and was replaced by the man he, in fact, replaced two years earlier: Ingmar Hoerr, CureVac’s founding CEO.

A week later, CureVac announced Hoerr would take a temporary leave of absence for medical (but not COVID-19-related) reasons and installed deputy CEO Franz-Werner Haas in Hoerr’s role “until his return.” But return he did not and earlier this month, Haas took “interim” off his job title.

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.